MDPI

Article

A Comprehensive In Silico Study of New Metabolites from *Heteroxenia fuscescens* with SARS-CoV-2 Inhibitory Activity

Fahd M. Abdelkarem [1], Alaa M. Nafady [1], Ahmed E. Allam [1,*], Mahmoud A. H. Mostafa [1,2], Rwaida A. Al Haidari [2], Heba Ali Hassan [3], Magdi E. A. Zaki [4,*], Hamdy K. Assaf [1], Mohamed R. Kamel [1], Sabry A. H. Zidan [1], Ahmed M. Sayed [5] and Kuniyoshi Shimizu [6]

1   Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt
2   Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al Madinah Al Munawarah 41477, Saudi Arabia
3   Department of Pharmacognosy, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt
4   Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia
5   Department of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt
6   Department of Agro-Environmental Sciences, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka 819-0395, Japan
*   Correspondence: ahmedallam@azhar.edu.eg (A.E.A.); mezaki@imamu.edu.sa (M.E.A.Z.)

Abstract: Chemical investigation of the total extract of the Egyptian soft coral *Heteroxenia fuscescens*, led to the isolation of eight compounds, including two new metabolites, sesquiterpene fusceterpene A (**1**) and a sterol fuscesterol A (**4**), along with six known compounds. The structures of **1–8** were elucidated via intensive studies of their 1D, 2D-NMR, and HR-MS analyses, as well as a comparison of their spectral data with those mentioned in the literature. Subsequent comprehensive in-silico-based investigations against almost all viral proteins, including those of the new variants, e.g., Omicron, revealed the most probable target for these isolated compounds, which was found to be M^{pro}. Additionally, the dynamic modes of interaction of the putatively active compounds were highlighted, depending on 50-ns-long MDS. In conclusion, the structural information provided in the current investigation highlights the antiviral potential of *H. fuscescens* metabolites with 3β,5α,6β-trihydroxy steroids with different nuclei against SARS-CoV-2, including newly widespread variants.

Keywords: sterol; virus; sesquiterpene; soft coral; in silico; molecular dynamic simulation; docking

1. Introduction

The global pandemic caused by coronavirus 2 (SARS-CoV-2) has taken many lives [1,2] from 2019 until the present. Several variants and outbreaks are still present in countries such as China and Korea [3].

Coronaviruses are a family of viruses that can cause a wide array of enteric, hepatic, neurological, and respiratory diseases [1]. The four subfamilies of coronavirus are α, β, γ, and δ, and are sorted based on genotype and serotype data [4]. Six species of coronaviruses cause human diseases. The most pathogenic and fatal species are Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SARS-CoV-2 is the seventh type, which infects humans and is related to the β lineage of the beta-coronaviruses, which are known to cause severe disease and fatalities [4]. Based on genomic analysis, SARS-CoV-2 belongs to two bat-derived SARS-like coronaviruses with 96% similarity, whereas its similarity to SARS-CoV is 79% [5]. The lung is the primary site and the most affected organ of SARS-CoV-2 infection. The clinical manifestations range from asymptomatic to severe respiratory disease. The most common symptoms of infection are a loss of smell and taste, fever, headache, shortness of breath, cough, muscle aches, and tiredness [6].

The coronaviral genome encodes four structural proteins, namely the envelope (E) protein, membrane (M) protein, nucleocapsid (N) protein, and spike (S) protein [5]. Most vaccine strategies have been focused on the spike protein, as it plays an essential role in viral entry to the host cell [5]. The E protein and M protein participate in the production and release of virus-like particles, while the N protein is a critical for viral replication and genome packaging [7,8]. During virus infection, the main proteases (M^{pro}) and cyclin-dependent kinases (CDKs) play a crucial role in the regulation and progression of cell division, which is essential in replication and viral transmissibility [9,10]. The main protease (M^{pro}) is essential for processing the polyproteins that are translated from the viral RNA, and SARS-CoV-2 modifies the CDK signaling pathway and regulates the cell division cycle in a way that leads to the enhancement of viral replication [11,12]. Consequently, M^{Pro} and CDK inhibitors are considered attractive targets for drugs that are used to treat the SARS-CoV-2 virus [13].

To speed up the treatment process, several antiviral drugs have been re-evaluated as an emerging antiviral option in the SARS-CoV-2 infection. Favipiravir has shown promising results in clinical studies in Japan, Russia, and China. Additionally, the oral antiviral drug nirmatrelvir/ritonavir (Paxlovid) has been approved by the FDA for emergency use [14].

Naturally occurring metabolites have proven to be promising sources of drug leads and structural motifs, based on the diversity of their structures and biological activities [15–17]. Several compounds, such as sesquiterpenes, diterpenes, steroids, alkaloids, and lipid derivatives, were isolated from soft corals [18–20]. Soft corals belonging to the family Xeniidea (Alcyonacea) are distributed throughout the oceans and seas [21,22], and the two genera that have been subjected to detailed chemical and biological investigation in the Red Sea are *Xenia* and *Heteroxenia* [23,24]. The genus *Heteroxenia* is distributed along the Egyptian Red Sea's coast, with two common species, *Heteroxenia fuscescens* and *Heteroxenia ghardaqensis* [21]. Several secondary metabolites, such as steroids (with a high degree of oxygenation), sesquiterpenoids, ceramides, and glycerol derivatives, were isolated from both species. Many of these metabolites showed diverse biological activities, such as anticancer, anti-inflammatory, anti-diabetic, and analgesic activities [24–30].

Based on the above data, as well as the urgent necessity of developing and searching for natural drugs to treat the SARS-CoV-2 virus, the isolation of the secondary metabolites of the soft coral *Heteroxenia fuscescens*, followed by the in silico prediction of isolated compounds as potential inhibitors of M^{pro} and Cyclin-G-associated kinase (GAK) and a promising scaffold using molecular docking and modeling analysis, were carried out.

2. Results

2.1. Identification of the Isolated Compounds

The crude extract of *H. fuscescens* was partitioned into fractions and isolated using several chromatographic techniques to yield eight compounds (**1–8**) (Figure 1). The structures of the known compounds were elucidated to be 3β,6β-dihydroxy-10β-hydroperoxycadin-4,8-diene, (**2**) [25], gorgost-5-(E)-ene-3-β-ol (**3**) [31,32], gorgost-3β,5α,6β,11α-tetrol (**5**) [33,34], 11α-acetoxy-gorgost-3β,5α,6β-triol (**6**) [30,35], 14α,15α-epoxy-23,24-dimethylcholesta,3β,5α, 6β,11α,20α-pentol (**7**) [25], and 3β,5α,6β-trihydroxyandrosta-17-one (**8**) [25], based on comparisons of their 1D (^{1}H and ^{13}C) NMR spectroscopic data against the data in the literature (Tables S1–S3 and Figures S20–S31 in Supplementary Materials).

Compound **1** was obtained as a colorless oil. The positive HR-FAB-MS showed a [M+H]$^{+}$ at *m/z* 235.1701 (calcd for $C_{15}H_{23}O_2$, 235.1698) and a base peak at [M-H$_2$O+H]$^{+}$ *m/z* 217.1605 (calcd for $C_{15}H_{21}O$, 217.1592); together with NMR spectroscopic data, the molecular formula was established to be $C_{15}H_{22}O_2$, with five degrees of unsaturation (Figure S1).

Figure 1. Structure of the isolated compounds (**1**)–(**8**) from *H. fuscescens*.

The combined analysis of the ^{13}C-NMR and HSQC spectra displayed 15 signals (Figures S4 and S5), which were categorized as four quaternary carbons (including three aromatic carbons at δ_C 139.5, 137.7, and 136.8, and one oxygenated at δ_C 74.5), six methines (including three aromatic carbons at δ_C 125.4, 127.5, and 128.8, and one oxygenated carbon at δ_C 73.8), one methylene at δ_C 27.3, and four methyls (including two quaternaries at δ_C 21.2, and 24.3, and two tertiaries at δ_C 18.0 and 21.6). The ^{1}H-NMR spectrum (Figures S2 and S3) indicated the presence of three aromatic protons, including two ortho-coupling protons at δ_H 7.5 (d, J = 7.9 Hz, H-2) and δ_H 7.1 (d, J = 7.9 Hz, H-3), and one singlet proton at δ_H 7.0 (s, H-5). One oxygenated proton at δ_H 4.0 (dd, J = 11.7, 3.9 Hz, H-9), two quaternary methyls at [δ_H 1.4 (s, H$_3$-14), 2.3 (s, H$_3$-15)], and two tertiary methyls at [δ_H 0.78 (d, J = 7.3 Hz, H$_3$-13), δ_H 1.06 (d, J = 7.1 Hz, H$_3$-12)]. Three double bonds accounted for three degrees of unsaturation; consequently, the remaining degrees were due to the bicyclic structure of **1**. From these data, compound **1** is assumed to be a bicyclic calamenene-type sesquiterpene [36,37] with two oxygenated carbons. The assignment of all carbons and protons, as well as the structure of compound **1**, was elucidated based on the extensive analysis of 2D NMR (^{1}H-^{1}H COSY, HSQC, and HMBC).

The HMBC spectrum (Figure 2 and Figure S6) clearly illustrated the attachment of H$_3$-15 at C-4 via the presence of a correlation between the two ortho-coupling protons H-2 and H-3, and the observed correlations between H$_3$-15 and C-3, C-4, and C-5. The second quaternary methyl H$_3$-14 was attached to the oxygenated carbon C-10 based on the

existence of cross-peaks between H_3-14 and C-1, C-9, and C-10. The second oxygenated carbon was C-9, based on the downfield shift of H-9 δ_H 4.0 (dd, *J* = 11.7, 3.9 Hz, H-9), while the isopropyl moiety was attached to C-7 based on the HMBC correlations between H_3-12 and C-7, C-11, and C-13; and between H_3-13 and C-7, C-11, and C-12, respectively. The ^{1}H-^{1}H COSY spectrum (Figures S7 and S8) illustrated the presence of two discrete spins corresponding to H-2/H-3 in the aromatic ring and H-9/H_2-8, H_2-8/H-7, H-7/H-11, H-11/H_3-12, and H-11/H_3-13, which confirmed the overall structure of compound **1**.


Figure 2. Key HMBC (⟶) and ^{1}H-^{1}H COSY (▬) correlations of compounds **1** (**a**) and **4** (**b**).

The relative configuration of compound **1** (7R*,9S*,10R*)-*cis* calamenene was deduced from the investigation via 1D and 2D NMR analyses (Figure 3, Figures S9 and S10), and via a comparison with the previously reported data of related compounds [38,39]. In particular, the main NOE correlations were observed between H-9 and H_3-14. Additionally, the absence of an NOE correlation between H-9 or H_3-14 and H-7 indicated that H-9 and H_3-14 are in one direction, and H-7 is in the other direction. By comparing the chemical shifts of H-7 and C-7 (δ_H 2.84 m; δ_c 41.5) of compound **1** with relative metabolites as *cis*-muurola-4(14),5-diene with the ^{13}C-NMR chemical shift of C-7 (δ_c 51.7) and 3-hydroxy calamenene with the ^{13}C-NMR chemical shift of C-7 (δ_c 43.9) (Table 1) [38,39], we can conclude that the OH at C-9 and C-10 were β-oriented, while an isopropyl group at C-7 was α-oriented. From the above data, compound **1** is new, identified as (7R*,9S*,10R*) 9,10-dihydroxycalamenene and named fusceterpene A.


Figure 3. Key NOESY correlations of compounds **1** (**a**) and **4** (**b**).

Table 1. ^{1}H and ^{13}C NMR data of compound **1**.

Position	δ_H [a]			δ_C [a]
	Chemical Shift (ppm)	Multiplicity	[*J* in (Hz)]	
1	—	—	—	139.5
2	7.48	d	7.9	125.4
3	7.06	d	7.9	127.5
4	—	—	—	137.7
5	7.03	s	—	128.8
6	—	—	—	136.8
7	2.84	m	—	41.5
8	2.01	m	—	27.3
	and 1.85	m	—	
9	4.01	dd	3.9, 11.3	73.8
10	—	—	—	74.5
11	2.20	m	—	33.6
12	1.06	d	7.0	21.6
13	0.78	d	7.0	18.01
14	1.41	s	—	24.31
15	2.30	s	—	21.2

[a] Measured in CDCl$_3$, ^{1}H-NMR (600 MHz) and ^{13}C-NMR (150 MHz).

Fuscesterol A **4** was isolated as a white powder. The HR-ESI-MS of compound **4** exhibited a [M+Na]$^+$ peak at *m/z* 527.3673 corresponding to the molecular formula C$_{31}$H$_{52}$O$_5$ and implying six degrees of unsaturation (Figure 1). These observations were in agreement with 31 signals in the ^{13}C-NMR spectrum (Table 2 and Figure S13). They were clarified via an HSQC experiment (Figure S14) into six quaternary carbons (including one carbonyl at δ_C 172.8, 2 oxygenated at δ_C 87.7 and 76.6, and one olefinic at δ_C 152.3), eight methines (including two oxygenated at δ_C 76.4, 73.0), 10 methylenes (including one terminal olefinic at δ_C 112.0), and seven methyls. From the above data, compound **4** was a steroid in nature [40,41]. Four degrees of unsaturation were accounted for by the tetracyclic structure, one for vinylic methylene and one for carbonyl. The above data suggested that compound **4** was an acetoxylated dimethyl cholestane-type steroid with a terminal double bond on the side chain [42–44].

^{1}H-NMR data (Figure S12) showed signals for seven methyls, including four doublets at δ_H 0.93 (3H, *J* = 6.6 Hz), 0.89 (3H, *J* = 6.6 Hz), 0.80 (3H, *J* = 6.6 Hz), and 0.78 (3H, *J* = 6.6 Hz), which were assigned to H$_3$-26, H$_3$-27, H$_3$-28, and H$_3$-29, and two singlets at δ_H 0.65 and 1.18, assigned to H-18 and H-19, respectively. Two singlet signals at δ_H 5.14 s and 4.89 s were assigned to vinylic methylene at C-21. The location of the double bond was confirmed via the presence of cross-peaks between H$_2$-21 and C-17, C-20, and C-22 in the HMBC spectrum (Figure S15). The presence of a hydroxylated group at C-17 (87.7) neighboring the vinylic methylene was confirmed from the HMBC correlation between H$_2$-21, H$_3$-18, and H$_2$-16 with C-17. The downfield shift of the oxygenated methines at δ_H 5.17 (m) at C-3 was due to the attachment of an acetate moiety. The attachment was confirmed via the presence of cross-peaks between H-3 and C-2, C-4, and C-1′, respectively. The key ^{1}H-^{1}H COSY correlations were observed between H-2/H-3, H-3/H-4, H-7/H-8, H-14/H-15, and H-15/H-16 (Figures S16 and S17), which confirm the structure of compound **4**.

The relative stereochemistry of compound **4** was deduced based on an NOE correlation in the NOESY spectrum (Figures S18 and S19) and comparing the ^{1}H and ^{13}C-NMR with the relative metabolites [42,44]. The key NOESY H-3/H-4a (δ_H 1.58), H-4a/H-6, and H$_3$-19/H-4b (δ_H 2.16) indicated that OAc-3 and OH-6 were *β*-oriented. The *α*-orientation of the OH at C-5 and C-17 was clarified by comparing the ^{13}C-NMR of C-5 and C-17 (δ_C 76.6 and δc 87.7), respectively, with relative metabolites as (23*R*) methyl-ergosta-20-ene-3*β*,5*α*,6*β*,17*α*-tetrol (δ_C 76.9 & δc 87.7), gorgostan-3*β*,5*α*,6*β*-triol-11*α*-acetate (C-5 δ_C 76.5), and klyflaccisteroid A (C-17 δ_C 86.7) [30,42,44]. Additionally, the relative configuration of the side chain was confirmed from the good agreement with the ^{1}H and ^{13}C-NMR data (23*R*,

24*R*)-23,24-dimethyl-cholest-20-ene side chain. Based on the above finding, compound **4** was identified as (23*R**,24*R**)-3*β*-acetoxy-5*α*,6*β*,17*α*-trihydroxy-23,24-dimethylcholesta-20-ene and named fuscesterol A.

Table 2. ^{1}H and ^{13}C NMR data of compound **4**.

Position	δ_H [a]			δ_C [a]
	Chemical Shift (ppm)	Multiplicity	[*J* in (Hz)]	
1	1.67	m	—	33.3
	and 1.32	m	—	
2	1.79	m	—	27.9
	and 1.56	m	—	
3	5.17	m	—	73.0
4	2.16	m	—	38.0
	and 1.58 *	—	—	
5	—	—	—	76.6
6	3.46	t	3.0	76.4
7	1.75	m	—	35.2
	and 1.53	m	—	
8	1.73	m	—	32.1
9	1.43	m	—	46.4
10	—	—	—	39.5
11	1.44	m	—	22.1
12	1.72 *	—	—	32.2
	and 1.37	dt	3.6, 12.6	
13	—	—	—	49.9
14	1.9	m	—	51.0
15	1.70	m	—	24.3
	and 1.23	m	—	
16	2.35	td	3.0, 14.4	35.8
	and 1.57*	—	—	
17	—	—	—	87.7
18	0.65	s	—	16.3
19	1.18	s	—	17.2
20	—	—	—	152.3
21	5.14	br.s	—	112.0
	and 4.89	br.s	—	
22	2.02	m	—	41.5
23	1.93	m	—	33.8
24	1.12	m	—	45.3
25	1.65	m	—	32.0
26	0.93	d	6.6	20.7
27	0.89	d	6.6	21.4
28	0.80	d	6.6	11.8
29	0.78	d	6.6	14.0
1′	—	—	—	172.8
2′	1.98	s	—	21.9

[a] Measured in CD_3OD, ^{1}H-NMR (600 MHz) and ^{13}C-NMR (150 MHz). * Multiplicity not determined due to overlapping.

2.2. Molecular Docking and Molecular Dynamic Simulation Results

To putatively determine the most probable molecular target for compounds **1–8**, we virtually screened their structures against all currently available SARS-CoV-2 proteins that have been reported to be relevant to the viral life cycle or viral pathogenesis (https://swissmodel.expasy.org/repository/species/2697049; https://www.genome.jp/kegg-bin/show_pathway?hsa05171+H02398 (accessed on 1 September 2022); Table S1). Both M^{pro} and Cyclin-G-associated kinase (GAK) were the only proteins that were found to have considerable docking scores (<−8.0 kcal/mol) with compounds **4**, **7**, and **8** (for M^{pro}) and compounds **3–5** and **8** (for GAK).

The subsequent MDS validation experiments (50 ns long) revealed that the structures of compounds **4**–**7** and **8** were not good binders to GAK, because they were significantly unstable over the course of MDS, with an average RMSD ranging from 6Å to > 10 Å. Moreover, their calculated absolute binding free energy values ($\Delta G_{binding}$) indicated a low affinity toward GAK's binding site, and ranged from −2.5 to −3.2 kcal/mol.

In contrast, the structures of compounds **5**, **7**, and **8** have achieved stable binding over the course of 50 ns MDS runs, with average RMSDs ranging from 1.8 Å to 2.2 Å, and with $\Delta G_{binding}$ values of −8.6, −8.8, and −8.1 kcal/mol, respectively. Interestingly, the three steroids that shared the stable binding had a characteristic hydroxylation pattern at positions 3, 5, and 6 in rings A and B. In addition, we have reported that the triterpene class of compounds, which is structurally related to compounds **5**, **7**, and **8**, is a promising scaffold to develop new M[pro] inhibitors [45,46].

To investigate the binding mode of each compound inside the M[pro]'s active site, the most populated binding poses for each compound structure was extracted from their 50-ns-long MDS trajectories.

As shown in Figure 4, the binding modes of the investigated structures were different from each other. The structure of compound **5** established three stable H-bonds with THR-25, ASP-187, and GLN-189, in addition to two hydrophobic interactions with LEU-27 and MET-49. The structure of compound **7** also established three H-bonds, but with ASN-142, GLU-166, and GLN-189. Additionally, it interacted hydrophobically with LEU-27 and MET-49. Finally, the structure of compound 8 was able to form four stable H-bonds with VAL-42, TYR-54, ASN-142, and GLN-189, together with two hydrophobic interactions with LEU-27 and MET-49.


Figure 4. Binding modes of compounds **5**, **7**, and **8** along with the co-crystalized inhibitor ML188 (**A**–**D**, respectively) inside the active site of SARS-CoV-2′s M[pro] (PDB code: 7L0D). These binding modes were extracted from the 50-ns-long MDS trajectories as the most populated poses. (**E**): RMSDs of compounds **5**, **7**, and **8** along with the co-crystalized inhibitor ML188 inside the active site of SARS-CoV-2′s M[pro] over the course of 50-ns-long MDS.

3. Discussion

In the previous literature, several bioactive metabolites were isolated from soft corals, which have the ability to inhibit the SARS-CoV-2 M^{pro}, as depresosterol, lopophytosterol, and cholest-5-ene-3β,7β-diol [47]. These compounds form stable hydrogen bonding through a polyhydroxy group in their structure with the amino acid in the active pocket of the SARS M^{pro} [47]. In the genus *Heteroxenia* (family Xeniidae), several polyoxygenated steroids were isolated and showed diverse biological activity [24,25,27,28,42].

From the previous data, it can be concluded that GLN-189 was the key amino acid residue interacting with the three structures (i.e., compounds **5**, **7**, and **8**) via H-bonding, while both the LEU-27 and MET-49 amino acid residues were the only residues hydrophobically interacting with them. The active steroids (**5**, **7**, and **8**) were interacting with three of the amino acids (GLN-189, LEU-27, and MET-49), which were included in the active site pockets of the SARS-CoV-2 M^{pro} [5], illustrating its possible activity. The dynamic behaviors of the three structures were convergent, where they were highly fluctuating over the course of the simulation, in comparison with the co-crystalized inhibitor (Figure 4). Their average RMSDs were 2.4 Å, 2.6 Å, and 1.3 Å for compounds **5**, **7**, and **8**, respectively (Figure 4). The calculated radius of the gyration profile of M^{pro} in complex with each compound was also consistent, with an average of ~ 18.4 Å (Figure 5). With regard to the interaction energy of the three structures over the course of the simulation, they showed stable interaction energy profiles (i.e., electrostatic and van der Waals interaction energies), with an average of ~-80 kcal/mol (Figure 6). Accordingly, the calculated MM-PBSA binding energy of each compound (Table 3) was found to be convergent with or even higher than that of the co-crystalized inhibitor ML188, indicating the potential inhibitory activity of these compounds against the viral M^{pro}. Such structural information will be of great interest during the future development of novel M^{pro} inhibitors, depending on the scaffolds of these compounds (i.e., compounds **5**, **7**, and **8**).

Table 3. MM-PBSA binding free energies of compounds **5**, **7**, and **8** along with the co-crystalized inhibitor ML188 in complex with M^{pro}.

| Energy Component	Compound 5	Compound 7	Compound 8	Co-Crystalized Ligand
ΔG_{gas}	−33.828	−32.723	−31.746	−41.9382
ΔG_{solv}	17.1182	18.9182	19.8337	27.6434
ΔG_{Total}	−16.7094	−13.8044	−11.9126	−14.2948

Figure 5. Radius of gyration of M^{pro} in complex with compounds **5**, **7**, and **8** along with the co-crystalized inhibitor ML188 (**A**–**D**, respectively) over the course of 50-ns-long MDS.

Figure 6. Interaction energy profiles of compounds **5**, **7**, and **8** along with the co-crystalized inhibitor ML188 in complex with M^{pro} (**A**–**D**, respectively) over the course of 50-ns-long MDS.

With regard to the probable inhibitory activity SARS-CoV-2's M^{pro} towards the isolated sesquiterpenes and sterols, docking, followed by MDS experiments, revealed that the polyhydroxylated sterols have good potential to bind with and to inhibit the enzyme's catalytic activity. According to the dynamic binding mode analysis, the stability of such derivatives was achieved inside the enzyme's active site through the formation of multiple H-bonds between the compounds' hydroxyl groups and a number of hydrophilic amino acids. Hence, losing such essential hydroxyl groups or masking them via acetylation might lead to unstable binding (i.e., compounds **3**, **4**, and **6**). Previously, a number of polyhydroxylated triterpenes (e.g., ursolic and maslinic acids) were found to significantly inhibit SARS-CoV's M^{pro} [48,49]. Hence, such steroidal or triterpenoidal scaffolds may be promising in the future development of novel M^{pro} inhibitors.

4. Materials and Methods

4.1. General Experimental Procedures

Optical rotations were recorded on a Jasco DIP-370 polarimeter. The 1D (^{1}H and ^{13}C) and 2D (HSQC, HMBC, ^{1}H-^{1}H COSY, and NOESY) NMR experiments were recorded on a Bruker DRX 600 NMR spectrometer (Bruker, Billerica, MA, USA). HR-ESI-MS and HR-FAB-MS were measured on an LC-MS-Q-TOF (Agilent Tokyo, Japan) and a JMS-700 mass spectrometer (JEOL, Tokyo, Japan), respectively. Coupling constants are expressed in Hz, and chemical shifts in δ (ppm). Chromatographic separations were performed using column chromatography on a Merck silica gel (70–230), and Medium-Pressure Liquid Chromatography (MPLC) (Büchi Reveleris® Prep system, Flawil, Switzerland) was performed using a silica gel cartridge (40 μM, 12 g) and a C-18 cartridge (WP, 20 μM, 4 g) with a UV-ELSD detector. Thin-layer chromatography (TLC) was performed on glass pre-coated silica gel 60 F$_{254}$ plates (Merck, Darmstadt, Germany) and reversed phase (RP-18 F$_{254}$), which were visualized under UV light at (254 and 365 nm) and sprayed with 5% MeOH-H$_2$SO$_4$ reagent, followed by heating for 2–3 min.

4.2. Animal Material

Heteroxenia fuscescens soft coral was collected and identified by Dr. Aldoushy Mahdy (Faculty of Science, Al-Azhar University, Assiut branch, Egypt) from the Red Sea in front of the National Institute of Oceanography and Fisheries, Hurghada, Egypt. A voucher sample (HF 20) has been deposited at the Pharmacognosy Department, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Egypt.

4.3. Extraction and Isolation

The fresh material of *H. fuscescens* (370 g) was sliced and exhaustively extracted with 90% MeOH. The total MeOH extract (8.9 g) was fractionated using silica gel CC and eluted with 100% *n*-Hexane, *n*-Hexane:EtOAc, EtOAc, and MeOH (100%) to obtain five fractions of *n*-Hexane (1.6 g), *n*-Hexane:EtOAc (50:50, 1.4 g), EtOAc (100%, 2.3 g), EtOAc:MeOH (50:50, 2.7 g), and MeOH (100%, 4.2 g). The *n*-Hexane:EtOAc (50:50) (1.4 g) fraction was passed over a normal flash column to yield four sub-fractions (HE I-IV). Sub-fraction (HE-I) was separated on silica gel CC using *n*-Hexane:EtOAc in a gradient manner to afford pure compound **2** (2.0 mg) and compound **3** (11.3 mg), which were finally purified via NPTLC using *n*-Hexane:EtOAc (40:60). Sub-fraction HE-II was separated by RP-18 MPLC using a MeOH-H_2O gradient from (30:70) to 100% MeOH to afford compound **1** (1.2 mg). Sub-fraction HE-IV was separated on NPTLC using *n*-Hexane:EtOAc (30:70) to obtain compound **4** (6.3 mg). The EtOAc fraction (2.3 g) was subjected to an RP-18 flash column using MeOH-H_2O in a gradient manner (50:50 to 80:20) to afford six sub-fractions (Et I–VI). Compound **8** (2.2 mg) was obtained from sub-fraction Et II by using RP_{18}-TLC and using (MeOH: H_2O, 70:30) as a solvent system. Sub-fraction Et IV was passed over Sephadex (LH-20) and eluted with MeOH 100% to obtain compound **5** (10.2 mg) and compound **7** (3.1 mg). Compound **6** (4.2 mg) was obtained from sub-fraction VI, which passed over silica gel CC and was eluted with *n*-Hexane:EtOAc (85:15) to EtOAc:MeOH (90:10).

4.4. Spectral Data

4.4.1. Fusceterpene A (**1**)

Colorless oil; $[a]_D^{20}$ + 62.2 (c 0.001, MeOH); for ^{1}H and ^{13}C-NMR data, see (Table 1). Positive HR-FAB-MS 235.1701 [M+H]$^+$ (calcd for $C_{15}H_{23}O_2$, 235.1698 *m/z*).

4.4.2. Fuscesterol A (**4**)

White amorphous powder; $[a]_D^{20}$ + 25.4 (c 0.002, MeOH); for ^{1}H and ^{13}C-NMR data, see (Table 2). Positive HR-ESI-MS at *m/z* 527.3673 [M+Na]$^+$ (calcd for $C_{31}H_{52}NaO_5$, 527.3712 *m/z*).

4.5. Molecular Docking and Molecular Dynamic Simulation

(See Supplementary Materials).

5. Conclusions

This study highlighted the significance of identifying antiviral secondary metabolites from the Red Sea's soft corals as naturally occurring SARS-CoV-2 inhibitors. A new steroid and a new sesquiterpene, along with six known compounds, were effectively isolated and structurally characterized, and they were essentially evaluated via in silico study against SARS-CoV-2 proteins. Through a stable hydrogen bond, the purified steroids containing a (3*β*,5*α*,6*β*-trihydroxy) moiety interact with the amino acid residue GLU-189, which highlights it as a perfect framework for the future creation of SARS-CoV-2 M^{pro} inhibitory medications.

References

1. Nair, R.; Soni, M.; Bajpai, B.; Dhiman, G.; Sagayam, K.M. Predicting the death rate around the world due to COVID-19 using regression analysis. *Int. J. Swarm Intell. Res.* **2022**, *13*, 1–13. [CrossRef]
2. Allam, A.E.; Assaf, H.K.; Hassan, H.A.; Shimizu, K.; Elshaier, Y.A. An in silico perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of COVID-19. *RSC Adv.* **2020**, *10*, 29983–29998. [CrossRef]
3. Hwang, S.M.; Jung, Y.; Seo, H. Diagnostic Laboratory Characteristics of COVID-19 Patients Infected by Fomites: COVID-19 Outbreak in a South Korean Public Administrative Facility. *Pathogens* **2022**, *11*, 700. [CrossRef] [PubMed]
4. Shamsi, A.; Mohammad, T.; Anwar, S.; Amani, S.; Khan, M.S.; Husain, F.M.; Rehman, M.T.; Islam, A.; Hassan, M.I. Potential drug targets of SARS-CoV-2: From genomics to therapeutics. *Int. J. Biol. Macromol.* **2021**, *177*, 1–9. [CrossRef] [PubMed]
5. Shamsi, A.; Mohammad, T.; Anwar, S.; AlAjmi, M.F.; Hussain, A.; Rehman, M.; Islam, A.; Hassan, M. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible implication in COVID-19 therapy. *Biosci. Rep.* **2020**, *40*, BSR20201256. [CrossRef] [PubMed]

6.   Esakandari, H.; Nabi-Afjadi, M.; Fakkari-Afjadi, J.; Farahmandian, N.; Miresmaeili, S.-M.; Bahreini, E. A comprehensive review of COVID-19 characteristics. *Biol. Proced. Online* **2020**, *22*, 1–10. [CrossRef] [PubMed]

7.   Saadat, K.A. RNAi-mediated siRNA sequences to combat the COVID-19 pandemic with the inhibition of SARS-CoV-2. *Gene Rep.* **2022**, *26*, 101512. [CrossRef]

8.   Abouelela, M.E.; Assaf, H.K.; Abdelhamid, R.A.; Elkhyat, E.S.; Sayed, A.M.; Oszako, T.; Belbahri, L.; El Zowalaty, A.E.; Abdelkader, M.S.A. Identification of potential SARS-CoV-2 main protease and spike protein inhibitors from the genus *aloe*: An in silico study for drug development. *Molecules* **2021**, *26*, 1767. [CrossRef] [PubMed]

9.   Roe, K. High COVID-19 virus replication rates, the creation of antigen–antibody immune complexes and indirect haemagglutination resulting in thrombosis. *Transbound. Emerg. Dis.* **2020**, *67*, 1418–1421. [CrossRef] [PubMed]

10.   Su, M.; Chen, Y.; Qi, S.; Shi, D.; Feng, L.; Sun, D. A mini-review on cell cycle regulation of coronavirus infection. *Front. Vet. Sci.* **2020**, *7*, 586826. [CrossRef] [PubMed]

11.   Meijer, L. Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. *Drug Resist. Updat.* **2000**, *3*, 83–88. [CrossRef]

12.   He, B.; Garmire, L. Prediction of repurposed drugs for treating lung injury in COVID-19. *F1000Research* **2020**, *9*, 609. [CrossRef]

13.   Owen, D.R.; Allerton, C.M.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science* **2021**, *374*, 1586–1593. [CrossRef] [PubMed]

14.   Parums, D.V. Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients. *Med. Sci. Monit.* **2022**, *28*, e935952-1–e935952-4. [CrossRef] [PubMed]

15.   Veríssimo, A.C.; Pacheco, M.; Silva, A.M.; Pinto, D.C. Secondary metabolites from marine sources with potential use as leads for anticancer applications. *Molecules* **2021**, *26*, 4292. [CrossRef] [PubMed]

16.   Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. *Nat. Rev. Drug Discov.* **2021**, *20*, 200–216. [CrossRef]

17.   Mahmoud, A.H.; Zidan, S.A.; Samy, M.N.; Alian, A.; Abdelmohsen, U.R.; Fouad, M.A.; Kamel, M.S.; Matsunami, K. Cytotoxicity and chemical profiling of the Red Sea soft corals *Litophyton arboreum*. *Nat. Prod. Res.* **2021**, *36*, 4261–4265. [CrossRef]

18.   Savić, M.P.; Sakač, M.N.; Kuzminac, I.Z.; Ajduković, J.J. Structural diversity of bioactive steroid compounds isolated from soft corals in the period 2015–2020. *J. Steroid Biochem. Mol. Biol.* **2022**, *2022*, 106061. [CrossRef] [PubMed]

19.   Abdelhafez, O.H.; Fahim, J.R.; Mustafa, M.; AboulMagd, A.M.; Desoukey, S.Y.; Hayallah, A.M.; Kamel, M.S.; Abdelmohsen, U.R. Natural metabolites from the soft coral *Nephthea* sp. as potential SARS-CoV-2 main protease inhibitors. *Nat. Prod. Res.* **2021**, *36*, 2893–2896. [CrossRef]

20.   Zidan, S.A.; Abdelhamid, R.A.; Al-Hammady, M.; Fouad, M.A.; Matsunami, K.; Orabi, M.A. Cytotoxic polyhydroxy sterols from the Egyptian Red Sea soft coral *Sarcophyton acutum*. *Fitoterapia* **2020**, *147*, 104765. [CrossRef]

21.   Ismail, H.A.; Hanafy, M.H.; Madkour, F.F.; Ahmed, M.I. Distribution of soft coral s in the Egyptian coasts of the Red Sea and Gulf of Aqaba. *Int. J. Eng. Sci.* **2017**, *7*, 14944.

22.   Koido, T.; Imahara, Y.; Fukami, H. High species diversity of the soft coral family Xeniidae (Octocorallia, Alcyonacea) in the temperate region of Japan revealed by morphological and molecular analyses. *ZooKeys* **2019**, *862*, 1. [CrossRef] [PubMed]

23.   Ng, S.Y.; Phan, C.S.; Ishii, T.; Kamada, T.; Hamada, T.; Vairappan, C.S. Terpenoids from Marine Soft Coral of the Genus *Xenia* in 1977 to 2019. *Molecules* **2020**, *25*, 5386. [CrossRef] [PubMed]

24.   Abdel-Razik, A.F.; Nassar, M.I.; Elshamy, A.I.; Kubacy, T.M.; Hegazy, M.E.F.; Ibrahim, N.; Le Lamer, A.C.; Farrag, A.R.H. A new cytotoxic ceramide from *Heteroxenia ghardaqensis* and protective effect of chloroform extract against cadmium toxicity in rats. *Arab. J. Chem.* **2016**, *9*, 649–655. [CrossRef]

25.   Abdelkarem, F.M.; Desoky, E.E.K.; Nafady, A.M.; Allam, A.E.; Mahdy, A.; Nagata, M.; Miyamoto, T.; Shimizu, K. Isolation of new secondary metabolites from gorgonian soft coral *Heteroxenia fuscescens* collected from Red Sea. *Phytochem. Lett.* **2020**, *36*, 156–161. [CrossRef]

26.   Abdel-Lateff, A.; Alarif, W.M.; Al-Lihaibi, S.S.; Abdel-Naim, A.B. Antiproliferative effects of selected marine organisms collected from Red Sea. *Pak. J. Pharm. Sci.* **2017**, *30*, 381–386. [PubMed]

27.   Mohammed, R.; Seliem, M.A.E.; Mohammed, T.; Abed-ElFatah, A.; Abo-Youssef, A.; Thabet, M. Bioactive secondary metabolites from the Red Sea soft coral *Heteroxenia fuscescens*. *Int. J. Appl. Res. Nat. Prod.* **2011**, *4*, 15–27.

28.   Edrada, R.A.; Wray, V.; Witte, L.; van Ofwegen, L.; Proksch, P. Bioactive terpenes from the soft coral *Heteroxenia* sp. from Mindoro, Philippines. *Z. Naturforsch C.* **2000**, *55*, 82–86. [CrossRef]

29.   Elshamy, A.I.; Nassar, M.I.; Mohamed, T.K.; Madkour, H.A. A new hydroxymethyl diacylglycerol from methanol extract of Egyptian soft coral *Heteroxenia ghardaqensis*. *J. Biol. Act. Prod. Nat.* **2015**, *5*, 172–177.

30.   Elshamy, A.I.; Abdel-Razik, A.F.; Nassar, M.I.; Mohamed, T.K.; Ibrahim, M.A.; El-Kousy, S.M. A new gorgostane derivative from the Egyptian Red Sea soft coral *Heteroxenia ghardaqensis*. *Nat. Prod. Res.* **2013**, *27*, 1250–1254. [CrossRef]

31.   Zidan, S.A.; Abdelhamid, R.A.; Alian, A.; Fouad, M.A.; Matsunami, K.; Orabi, M.A. Diterpenes and sterols from the Red Sea soft coral *Sarcophyton trocheliophorum* and their cytotoxicity and anti-leishmanial activities. *J. Asian Nat. Prod. Res.* **2021**, *24*, 794–802. [CrossRef] [PubMed]

32. Hegazy, M.E.F.; Mohamed, T.A.; Elshamy, A.I.; Hassanien, A.A.; Abdel-Azim, N.S.; Shreadah, M.A.; Abdelgawad, I.I.; Elkady, E.M.; Paré, P.W. A new steroid from the Red Sea soft coral *Lobophytum lobophytum*. *Nat. Prod. Res.* **2016**, *30*, 340–344. [CrossRef] [PubMed]

33. Umeyama, A.; Shoji, N.; Ozeki, M.; Arihara, S. Sarcoaldesterols A and B, two new polyhydroxylated sterols from the soft coral *Sarcophyton* sp. *J. Nat. Prod.* **1996**, *59*, 894–895. [CrossRef]

34. Cheng, Z.B.; Xiao, H.; Fan, C.Q.; Lu, Y.N.; Zhang, G.; Yin, S. Bioactive polyhydroxylated sterols from the marine sponge *Haliclona crassiloba*. *Steroids* **2013**, *78*, 1353–1358. [CrossRef] [PubMed]

35. Wang, Z.; Tang, H.; Wang, P.; Gong, W.; Xue, M.; Zhang, H.; Liu, T.; Liu, B.; Yi, Y.; Zhang, W. Bioactive polyoxygenated steroids from the South China sea soft coral, *Sarcophyton* sp. *Mar. Drugs* **2013**, *11*, 775–787. [CrossRef]

36. Konečný, K.; Streibl, M.; Vašíčková, S.; Buděšínský, M.; Šaman, D.; Ubik, K.; Herout, V. Constituents of the liverwort *Bazzania trilobata* of Czech origin. *Collect. Czechoslov. Chem. Commun.* **1985**, *50*, 80–93. [CrossRef]

37. Limna Mol, V.; Raveendran, T.; Naik, B.; Kunnath, R.; Parameswaran, P. Calamenenes–aromatic bicyclic sesquiterpenes–from the Indian gorgonian *Subergorgia reticulata* (Ellis and Solander, 1786). *Nat. Prod. Res.* **2011**, *25*, 169–174. [CrossRef]

38. Salmoun, M.; Braekman, J.C.; Ranarivelo, Y.; Rasamoelisendra, R.; Ralambomanana, D.; Dewelle, J.; Darro, F.; Kiss, R. New calamenene sesquiterpenes from *Tarenna madagascariensis*. *Nat. Prod. Res.* **2007**, *21*, 111–120. [CrossRef]

39. Young-Kyoon, K.; Cool, L.G.; Zavarin, E. cis-Calamenene-related sesquiterpenoids from *Cupressus bakeri* foliage. *Phytochemistry* **1994**, *36*, 961–965. [CrossRef]

40. Zhang, D.; Wang, Z.; Han, X.; Li, X.L.; Lu, Z.Y.; Dou, B.B.; Zhang, W.Z.; Tang, X.L.; Li, P.L.; Li, G.Q. Four bioactive new steroids from the soft coral *Lobophytum pauciflorum* collected in South China Sea. *Beilstein J. Org. Chem.* **2022**, *18*, 374–380. [CrossRef]

41. Ngoc, N.T.; Hanh, T.T.H.; Quang, T.H.; Cuong, N.X.; Nam, N.H.; Thung, D.C.; Van Kiem, P.; Van Minh, C. Polyhydroxylated steroids from the Vietnamese soft coral *Sarcophyton ehrenbergi*. *Steroids* **2021**, *176*, 108932. [CrossRef] [PubMed]

42. Abdelkarem, F.M.; Desoky, E.E.K.; Nafady, A.M.; Allam, A.E.; Mahdy, A.; Ashour, A.; Mohamed, G.A.; Miyamoto, T.; Shimizu, K. Two new polyhydroxylated steroids from Egyptian soft coral *Heteroxenia fuscescens* (Fam.; Xeniidae). *Nat. Prod. Res.* **2021**, *35*, 236–243. [CrossRef]

43. Tseng, W.R.; Huang, C.Y.; Tsai, Y.Y.; Lin, Y.S.; Hwang, T.L.; Su, J.H.; Sung, P.J.; Dai, C.F.; Sheu, J.H. New cytotoxic and anti-inflammatory steroids from the soft coral *Klyxum flaccidum*. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 3253–3257. [CrossRef] [PubMed]

44. Tsai, C.R.; Huang, C.Y.; Chen, B.W.; Tsai, Y.Y.; Shih, S.P.; Hwang, T.L.; Dai, C.F.; Wang, S.Y.; Sheu, J.H. New bioactive steroids from the soft coral *Klyxum flaccidum*. *RSC Adv.* **2015**, *5*, 12546–12554. [CrossRef]

45. Alhadrami, H.A.; Burgio, G.; Thissera, B.; Orfali, R.; Jiffri, S.E.; Yaseen, M.; Sayed, A.M.; Rateb, M.E. Neoechinulin A as a promising SARS-CoV-2 Mpro inhibitor: In vitro and in silico study showing the ability of simulations in discerning active from inactive enzyme inhibitors. *Mar. Drugs* **2022**, *20*, 163. [CrossRef] [PubMed]

46. Abd El Hafez, M.S.; AbdEl-Wahab, M.G.; Seadawy, M.G.; El-Hosseny, M.F.; Beskales, O.; Abdel-Hamid, A.S.A.; El Demellawy, M.A.; Ghareeb, D.A. Characterization, in-silico, and in-vitro study of a new steroid derivative from *Ophiocoma dentata* as a potential treatment for COVID-19. *Sci. Rep.* **2022**, *12*, 1–11. [CrossRef]

47. Ibrahim, M.A.; Abdelrahman, A.H.; Mohamed, T.A.; Atia, M.A.; Al-Hammady, M.A.; Abdeljawaad, K.A.; Elkady, E.M.; Moustafa, M.F.; Alrumaihi, F.; Allemailem, K.S. In silico mining of terpenes from red-sea invertebrates for SARS-CoV-2 main protease (M^{pro}) inhibitors. *Molecules* **2021**, *26*, 2082. [CrossRef]

48. Alhadrami, H.A.; Sayed, A.M.; Sharif, A.M.; Azhar, E.I.; Rateb, M.E. Olive-derived triterpenes suppress SARS-CoV-2 main protease: A promising scaffold for future therapeutics. *Molecules* **2021**, *26*, 2654. [CrossRef]

49. Wen, C.C.; Kuo, Y.H.; Jan, J.T.; Liang, P.H.; Wang, S.Y.; Liu, H.G.; Lee, C.K.; Chang, S.T.; Kuo, C.J.; Lee, S.S. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *J. Med. Chem.* **2007**, *50*, 4087–4095. [CrossRef]

50. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. *J. Comput. Aided Mol. Des.* **2010**, *24*, 417–422. [CrossRef]

51. Clyde, A.; Galanie, S.; Kneller, D.W.; Ma, H.; Babuji, Y.; Blaiszik, B.; Brace, A.; Brettin, T.; Chard, K.; Chard, R.; et al. High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor. *J. Chem. Inf. Model.* **2022**, *62*, 116–128. [CrossRef] [PubMed]

52. Sayed, A.M.; Alhadrami, H.A.; El-Gendy, A.O.; Shamikh, Y.I.; Belbahri, L.; Hassan, H.M.; Abdelmohsen, U.R.; Rateb, M.E. Microbial natural products as potential inhibitors of SARS-CoV-2 main protease (Mpro). *Microorganisms* **2020**, *8*, 970. [CrossRef] [PubMed]

53. Amaro, R.E.; Baudry, J.; Chodera, J.; Demir, Ö.; McCammon, J.A.; Miao, Y.; Smith, J.C. Ensemble docking in drug discovery. *Biophys. J.* **2018**, *114*, 2271–2278. [CrossRef] [PubMed]

54. Bowers, K.J.; Chow, D.E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. In Proceedings of the SC'06: 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006; IEEE: New York, NY, USA, 2006; p. 43.

55. Release, S. *3: Desmond Molecular Dynamics System, DE Shaw Research, New York, NY, 2017*; Maestro-Desmond Interoperability Tools; Schrödinger: New York, NY, USA, 2017.

56. Schrodinger LLC Maestro. Version 9.0. Schrodinger LLC: New York, NY, USA, 2009.

57. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. *J. Comput. Chem.* **2005**, *26*, 1781–1802. [CrossRef]

58. Kim, S.; Oshima, H.; Zhang, H.; Kern, N.R.; Re, S.; Lee, J.; Rous, B.; Sugita, Y.; Jiang, W.; Im, W. CHARMM-GUI free energy calculator for absolute and relative ligand solvation and binding free energy simulations. *J. Chem. Theory Comput.* **2020**, *16*, 7207–7218. [CrossRef]

59. Ngo, S.T.; Tam, N.M.; Quan, P.M.; Nguyen, T.H. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro. *J. Chem. Inf. Model.* **2021**, *61*, 2302–2312. [CrossRef]

60. Miller, B.R., III; McGee, T.D., Jr.; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA. py: An efficient program for end-state free energy calculations. *J. Chem. Theory Comput.* **2012**, *8*, 3314–3321. [CrossRef]